Predicting Pathological Response Within the 1st Week of Chemotherapy Using Diffuse Optical Spectroscopic Imaging

Withdrawn before enrolling

Conditions studied: Breast Cancer

In brief

Women with Breast Cancer who do not respond to chemotherapy may undergo months of treatment with little or no change in tumor size or overall outcome. The Researchers have demonstrated a previously undescribed "metabolic flare" response observed very early in neoadjuvant treatment in breast cancer patients. The research can determine that this flare is predictive of overall therapy response and is due to both an inflammatory reaction and cell death induced by cytotoxic therapy.

Key facts

Study ID

NCT01277263

Run by

University of California, Irvine

People needed

0

Starts

2010-12-01

Expected to finish

2018-12-01

Last updated by the study team

2022-11-01

Who can join

Age: 21 and older, up to 75. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Female, not pregnant, not breastfeeding
• greater than 21 years of age but less than 75 years of age
• will be receiving neoadjuvant chemotherapy for breast cancer as prescribed by their oncologist

You may not qualify if…

• Under 21 year of age
• Female pregnant or breastfeeding

Where it is running

• Pacific Breast Care Medical Clinic — Costa Mesa, California, United States
• Beckman Laser Institute — Irvine, California, United States
• Chao Family Comprehensive Cancer Center, UCIMC — Orange, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.